leisure time -WSS

leisure time

author：focus 2025-10-02 22:41:20 - browse：514

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA panel to weigh safety of artificial wombs for preterm births

leisure time

WSS

Mom launches Girl Scout troop for LGBTQ youth in Texas

PBMs drew scrutiny in House hearing — and so did pharma

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

A public health expert passes on football's full body collisions for youths

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

leisure time

leisure time

knowledge

New air purifier tech could be key to improving indoor air quality

Covid’s new normal has set in amid another rise in cases

In Memoriam: Notable people who died in 2023

Bispecific antibodies are next new thing in cancer immunotherapy

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

New air purifier tech could be key to improving indoor air quality

Akili changes sales model for its ADHD video game treatment

New air purifier tech could be key to improving indoor air quality

People with substance use disorder deserve online privacy

entertainment

Information blocking fines are now fair game in health care

Can medical device makers keep up in the race to treat obesity?

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Reanimated hearts work just as well for transplants, study finds

FDA panel to weigh safety of artificial wombs for preterm births

The thinking behind the controversial eating disorder chatbot Tessa

Wikipedia

hotspot

leisure time

knowledge